Galderma Group AG
SIX:GALD
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
53
97
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Galderma Group AG
Research & Development
Galderma Group AG
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Galderma Group AG
SIX:GALD
|
Research & Development
-286.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Transocean Ltd
NYSE:RIG
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sealsq Corp
NASDAQ:LAES
|
Research & Development
-$3.9m
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
TalkPool AG
STO:TALK
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
R
|
R&S Group Holding AG
SIX:RSGN
|
Research & Development
-CHf479k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Galderma Group AG
Glance View
Galderma Group AG, a prominent player in the dermatological field, has carved a niche for itself since its inception in 1981 as a joint venture between Nestlé and L'Oréal. Now operating independently, Galderma journeys through the complex terrain of skin health, focusing keenly on prescription drugs, over-the-counter products, and aesthetics medicine. Its spectrum of offerings spans across dermatology segments—from treating acne and rosacea to pioneering advances in aesthetic treatments with its products like Restylane and Dysport. The company's core strategy revolves around leveraging its extensive R&D capabilities, ensuring that medical and aesthetic practitioners have cutting-edge solutions that address both therapeutic and enhancement demands. Revenue streams for Galderma primarily flow from its three business pillars—prescription, aesthetics, and consumer health solutions. The prescription segment engages dermatologists and healthcare providers, offering topicals and oral medications pivotal for serious skin conditions. The aesthetics division appeals to clinics and practitioners focusing on beauty and corrective procedures, while consumer health offers OTC solutions direct to customers for daily skin concerns. Galderma capitalizes on strategic alliances and partnerships, ensuring robust distribution channels, and invests heavily in innovation, staying at the forefront of the fast-evolving dermatology landscape. With a presence in over 100 countries, Galderma has made a mark by blending medical rigor with consumer accessibility, anchoring its success in its in-depth understanding of skin health and nuanced market needs.
See Also
What is Galderma Group AG's Research & Development?
Research & Development
-286.9m
Based on the financial report for Dec 31, 2023, Galderma Group AG's Research & Development amounts to -286.9m .
What is Galderma Group AG's Research & Development growth rate?
Research & Development CAGR 1Y
9%
Over the last year, the Research & Development growth was 9%.
You don't have any saved screeners yet
